Skip to content

US · TENX · BIOTECHNOLOGY

Tenax Therapeutics, Inc. (TENX) intrinsic value and stock valuation

$1.25as of 2026-11-21 · Mkt cap 346.15M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tenax Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TENX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TENX’s statements →

Tenax Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Chapel Hill, NC 27517 tenaxthera.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-52.6M
20112025
Free cash flow
-$-35.8M
20112025
Total equity
$97.1M+83.8% 5y CAGRd
20102025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-56.38M-$-19.49M-$-8.23M-$-11.05M-$-32.73M
Net income-$-52.6M-$-17.6M-$-7.71M-$-11.05M-$-32.47M
EPSd-$-1.34M-$-1.15M-$-30.84M-$-552.5M-$-3.25B
Operating cash flow-$-35.8M-$-14.81M-$-5.9M-$-12.01M-$-10.86M
Capital expenditure$0.00$0.00$0.00-$0.00-$-10K
Free cash flow-$-35.8M-$-14.81M-$-5.9M-$-12.02M-$-10.86M
Total assets$104.2M$96.7M$11.7M$3.4M$5.99M
Total debt$0.00$0.00$500K$810K$290K
Net debt-$-97.56M-$-94.85M-$-9.29M-$-1.32M-$-5.29M
Total equity$97.1M$92M$8.1M$1.49M$4.24M
Cash and short-term investments$97.6M$94.9M$9.79M$2.12M$5.58M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$32.7M$12.7M$3.23M$5.38M$25.2M
Selling, general and administrative expenses$23.7M$6.79M$5M$5.68M$7.58M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$56.4M$19.5M$8.23M$11.1M$32.7M
Cost and expenses$56.4M$19.5M$8.23M$11.1M$32.7M
Interest income$3.82M$1.91M$0.00$0.00$0.00
Interest expense$0.00$20K$20K$0.00$0.00
Depreciation and amortization$0.00$0.00$10K$110K$110K
Ebitda-$-52.6M-$-17.58M-$-7.68M-$-10.93M-$-32.36M
Operating income-$-56.38M-$-19.49M-$-8.23M-$-11.05M-$-32.73M
Total other income/expenses, net$3.79M$1.89M$520K$0.00$250K
Income before tax-$-52.6M-$-17.6M-$-7.71M-$-11.05M-$-32.47M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-52.6M-$-17.6M-$-7.71M-$-11.05M-$-32.47M
Weighted average shares outstanding$39.2M$15.3M$250K$20K$10K
Weighted average diluted shares outstanding$39.2M$15.3M$250K$20K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$97.6M$94.9M$9.79M$2.12M$5.58M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$104.2M$96.7M$11.7M$3.21M$5.69M
Property, plant and equipment, net$0.00$0.00$0.00$190K$290K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$200K$300K
Total assets$104.2M$96.7M$11.7M$3.4M$5.99M
Accounts payable$6.04M$3.16M$2.07M$450K$860K
Short-term debt$0.00$0.00$500K$740K$110K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.16M$4.69M$3.59M$1.85M$1.56M
Long-term debt$0.00$0.00$0.00$60K$180K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$60K$180K
Capital lease obligations$0.00$0.00$0.00$180K$290K
Total liabilities$7.16M$4.69M$3.59M$1.91M$1.75M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-367.45M-$-314.86M-$-297.25M-$-289.54M-$-278.49M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$97.1M$92M$8.1M$1.49M$4.24M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$500K$810K$290K
Net debt-$-97.56M-$-94.85M-$-9.29M-$-1.32M-$-5.29M
Cash flow statement
20252024202320222021
Net income-$-52.6M-$-17.6M-$-7.71M-$-11.05M-$-32.47M
Depreciation and amortization$0.00$0.00$10K$110K$110K
Stock-based compensation$0.00$1.12M$190K$0.00$0.00
Change in working capital-$-2.36M$1.64M$1.58M-$-1.45M-$-610K
Accounts receivable$0.00$60K-$-310K$0.00-$-20K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.88M$1.06M$1.65M-$-340K$0.00
Net cash provided by operating activities-$-35.8M-$-14.81M-$-5.9M-$-12.01M-$-10.86M
Investments in property, plant and equipment$0.00$0.00$0.00-$0.00-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00-$0.00$450K
Common stock issued$38.5M$100.4M$14.2M$7.93M$9.19M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$38.5M$99.9M$13.6M$8.55M$9.74M
Net change in cash$2.71M$85.1M$7.67M-$-3.46M-$-670K
Cash at end of period$97.6M$94.9M$9.79M$2.12M$5.58M
Operating cash flow-$-35.8M-$-14.81M-$-5.9M-$-12.01M-$-10.86M
Capital expenditure$0.00$0.00$0.00-$0.00-$-10K
Free cash flow-$-35.8M-$-14.81M-$-5.9M-$-12.02M-$-10.86M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tenax Therapeutics, Inc.

        Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.

        CEO
        Christopher T. Giordano
        Employees
        16
        Beta
        0.91

        Explore

        Frequently asked questions

        What is the intrinsic value of Tenax Therapeutics, Inc. (TENX)?

        InvestorsCraft does not currently publish an intrinsic value for TENX. How the IC value is calculated.

        Is TENX undervalued?

        InvestorsCraft does not publish an undervaluation signal for TENX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.